导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.37% | 1399/4773 |
| 近一周 | -2.62% | 2703/5462 |
| 近一月 | -3.96% | 2108/5421 |
| 近一季 | -5.03% | 1752/5209 |
| 近半年 | -5.35% | 2829/4920 |
| 近一年 | 8.92% | 1137/4366 |
| 近两年 | 77.98% | 835/2954 |
| 近三年 | 48.24% | 566/2253 |
| 成立以来 | 97.85% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.37% 1302/4961 |
8.70% 2559/5312 |
- - |
- - |
| 2025 | 34.59% 1032/4813 |
3.42% 1089/3635 |
3.69% 963/4076 |
22.67% 1626/4524 |
2.30% 1005/4813 |
| 2024 | 10.69% 1385/3463 |
-0.67% 1136/2808 |
-2.80% 1254/3014 |
13.48% 2162/3129 |
1.02% 1133/3463 |
| 2023 | -3.67% 647/2656 |
5.78% 755/2280 |
-3.24% 757/2385 |
-2.00% 612/2515 |
-3.96% 830/2655 |
| 2022 | -14.84% 395/2207 |
-13.23% 719/1919 |
5.80% 821/2016 |
-9.84% 317/2113 |
2.89% 807/2208 |
| 2021 | 15.54% 304/1822 |
-0.26% 345/1255 |
6.96% 711/1330 |
5.61% 264/1466 |
2.55% 564/1822 |
| 2020 | 31.80% 495/1250 |
-2.93% 280/1028 |
20.55% 270/1067 |
9.17% 667/1164 |
3.16% 941/1184 |
| 2019 | 27.23% 554/1092 |
27.81% 333/754 |
-6.92% 532/804 |
1.30% 416/850 |
5.57% 703/918 |
| 2018 | -31.28% 492/834 |
- - |
- - |
- - |
-11.82% 358/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 招商中证500指数C VS. 长安沪深300非周期A(740101) |